3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
7
Prostatic Neoplasms
4
Brain Neoplasms
4
Neoplasms
3
Neoplasm Metastasis
3
Sarcoma
2
Multiple Myeloma
2
Lung Neoplasms
2
Glioma
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Fatigue
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Weight Loss
1
Uterine Cervical Neoplasms
1
Thrombocytopenia
1
Symptom Management
1
Stomach Neoplasms
1
Splenomegaly
1
Sexual Dysfunction, Physiological
1
Sex Cord-Gonadal Stromal Tumors
1
Sarcoma, Synovial
1
Rectal Neoplasms
1
Peritoneal Neoplasms
1
Pain
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neuroendocrine Tumors
1
Neoplasms, Germ Cell and Embryonal
1
Interventions
Nivolumab
20
Ipilimumab
10
Paclitaxel
7
linrodostat
6
Standard of Care
6
Sirolimus
5
Gemcitabine
5
Bevacizumab
5
temsirolimus
4
relatlimab
4
Pemetrexed
4
Docetaxel
4
Carboplatin
4
ARRY-334543
4
Vorinostat
3
Erlotinib Hydrochloride
3
Dasatinib
3
Cetuximab
3
regorafenib
2
olaparib
2
apatinib
2
anlotinib
2
abemaciclib
2
Trastuzumab
2
Surveys and Questionnaires
2
Sunitinib
2
Sorafenib
2
Olanzapine
2
N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
2
Magnetic Resonance Spectroscopy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Advanced Cancer
×
Quality of Life
×
Clear all
NCT01444157
2014-07-18
FamCope
Bispebjerg Hospital
Phase 3
Completed
700 enrolled